Michael Dennis, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Dennis, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07513324 · Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)Dana-Farber Cancer Institute · withdrawn · HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma · principal investigator
- Ph2NCT06239220 · PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCCDana-Farber Cancer Institute · recruiting · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer · principal investigator
- Ph1/Ph2NCT05774899 · CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCMichael J. Dennis, MD · recruiting · Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.